Enzalutamide (Xtandi): An Androgen Receptor Antagonist for Late-Stage Prostate Cancer

Innovative Drug Synthesis ◽

10.1002/9781118819951.ch6 ◽

2015 ◽

pp. 99-118

Author(s):

Sha Lou ◽

Ji Zhang

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Androgen Receptor Antagonist

Download Full-text

Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)

Journal of Medicinal Chemistry ◽

10.1021/acs.jmedchem.0c01563 ◽

2021 ◽

Vol 64 (2) ◽

pp. 909-924 ◽

Author(s):

Zhuming Zhang ◽

Peter J. Connolly ◽

Heng Keang Lim ◽

Vineet Pande ◽

Lieven Meerpoel ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Clinical Stage ◽

Castration Resistant Prostate Cancer ◽

Wild Type ◽

Androgen Receptor Antagonist ◽

Castration Resistant

Download Full-text

The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor β1 expression in prostate cancer cells

Journal of Cellular Biochemistry ◽

10.1002/jcb.28929 ◽

2019 ◽

Vol 120 (10) ◽

pp. 16711-16722

Author(s):

Alexander Abazid ◽

Benedikt Martin ◽

Anja Choinowski ◽

Rhiannon V. McNeill ◽

Lars‐Ove Brandenburg ◽

...

Keyword(s):

Prostate Cancer ◽

Estrogen Receptor ◽

Androgen Receptor ◽

Heat Shock Protein ◽

Receptor Antagonist ◽

Cancer Cells ◽

Prostate Cancer Cells ◽

Protein System ◽

Androgen Receptor Antagonist

Download Full-text

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-06-0144 ◽

2007 ◽

Vol 6 (1) ◽

pp. 51-60 ◽

Author(s):

Deborah L. Marrocco ◽

Wayne D. Tilley ◽

Tina Bianco-Miotto ◽

Andreas Evdokiou ◽

Howard I. Scher ◽

...

Keyword(s):

Prostate Cancer ◽

Cell Proliferation ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Hydroxamic Acid ◽

Prostate Cancer Cell ◽

Receptor Expression ◽

Suberoylanilide Hydroxamic Acid ◽

Cancer Cell Proliferation ◽

Androgen Receptor Antagonist

Download Full-text

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

European Urology ◽

10.1016/j.eururo.2016.04.023 ◽

2016 ◽

Vol 70 (6) ◽

pp. 963-970 ◽

Author(s):

Matthew R. Smith ◽

Emmanuel S. Antonarakis ◽

Charles J. Ryan ◽

William R. Berry ◽

Neal D. Shore ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

High Risk ◽

Antitumor Activity ◽

Receptor Antagonist ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Androgen Receptor Antagonist ◽

Castration Resistant ◽

Download Full-text

Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer

ACS Medicinal Chemistry Letters ◽

10.1021/acsmedchemlett.5b00173 ◽

2015 ◽

Vol 6 (8) ◽

pp. 908-912 ◽

Author(s):

Aaron Balog ◽

Richard Rampulla ◽

Gregory S. Martin ◽

Stanley R. Krystek ◽

Ricardo Attar ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Androgen Receptor Antagonist

Download Full-text

Phospholipase C (PLC)ε Promotes Androgen Receptor Antagonist Resistance via the Bone Morphogenetic Protein (BMP)-6/SMAD Axis in a Castration-Resistant Prostate Cancer Cell Line

Medical Science Monitor ◽

10.12659/msm.915828 ◽

2019 ◽

Vol 25 ◽

pp. 4438-4449 ◽

Author(s):

Mengjuan Yuan ◽

Yingying Gao ◽

Luo Li ◽

Wei Sun ◽

Honglin Cheng ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Prostate Cancer Cell ◽

Cancer Cell Line ◽

Prostate Cancer Cell Line ◽

Castration Resistant Prostate Cancer ◽

Androgen Receptor Antagonist ◽

Castration Resistant ◽

Morphogenetic Protein

Download Full-text

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer

10.18632/oncotarget.8456 ◽

2016 ◽

Vol 7 (18) ◽

pp. 26259-26274 ◽

Author(s):

Steven Kregel ◽

James L. Chen ◽

Westin Tom ◽

Venkatesh Krishnan ◽

Jacob Kach ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Second Generation ◽

Acquired Resistance ◽

Castration Resistant Prostate Cancer ◽

Androgen Receptor Antagonist ◽

Castration Resistant

Download Full-text

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models

International Journal of Cancer ◽

10.1002/ijc.32242 ◽

2019 ◽

Vol 145 (5) ◽

pp. 1382-1394 ◽

Author(s):

Tatsuo Sugawara ◽

Simon J. Baumgart ◽

Ekaterina Nevedomskaya ◽

Kristin Reichert ◽

Holger Steuber ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Androgen Receptor Antagonist ◽

Download Full-text

Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer

European Journal of Cancer ◽

10.1016/j.ejca.2020.04.013 ◽

2020 ◽

Vol 134 ◽

pp. 29-40 ◽

Author(s):

Tie Zhou ◽

Weidong Xu ◽

Wei Zhang ◽

Ye Sun ◽

Honghua Yan ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Androgen Receptor ◽

Phase I ◽

Receptor Antagonist ◽

Phase I Clinical Trial ◽

Castration Resistant Prostate Cancer ◽

Androgen Receptor Antagonist ◽

Castration Resistant

Download Full-text

Abstract 1702: Androgen receptor antagonist bicalutamide sensitizes androgen-independent prostate cancer cells to mTOR inhibitor rapamycin by regulating phosphorylation of translation initiation suppressor eIF4E-binding protein 1 (4E-BP1)

10.1158/1538-7445.am10-1702 ◽

2010 ◽

Author(s):

Swagata Bose ◽

Yu Wang ◽

Salma Siddiqui ◽

Benjamin Mooso ◽

Ruth Vinall ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Cancer Cells ◽

Translation Initiation ◽

Mtor Inhibitor ◽

Binding Protein ◽

Prostate Cancer Cells ◽

Androgen Receptor Antagonist ◽

Androgen Independent

Download Full-text